Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Therapeutic advances in neurological disorders·2026
Same author

Anne-Katrin Pröbstel: B cells, antibodies and microbiota in autoimmune disease.

Nature reviews. Neurology·2026
Same author

Female-enriched <i>Eggerthella lenta</i> drives neuroinflammation and IFN-γ via host receptor TLR2.

bioRxiv : the preprint server for biology·2026
Same author

Host control of persistent Epstein-Barr virus infection.

Nature·2026
Same author

Publisher Correction: Lymphotoxin-dependent elevated meningeal CXCL13:BAFF ratios drive gray matter injury.

Nature immunology·2026
Same author

Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation.

Cell·2026

相关实验视频

Updated: Jan 14, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K

在渐进的多发性硬化症中使用免疫疗法.

Tradite Neziraj1, Ludwig Kappos2, Anne-Katrin Pröbstel3

  • 1Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Departments of Biomedicine and of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.

Handbook of clinical neurology
|January 12, 2026
PubMed
概括
此摘要是机器生成的。

多发性硬化症 (MS) 是一种自身免疫性中枢神经系统疾病. 进展,而不仅仅是复发,驱动残疾,需要专注于潜在的神经退行过程的有效治疗.

关键词:
B 细胞 B 细胞 B 细胞免疫调节是一种免疫调节.炎症 炎症是一种炎症.多发性硬化症是多发性硬化症.神经退行发生神经退行.原发性渐进性多发性硬化一个进步的进步.

更多相关视频

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.5K

相关实验视频

Last Updated: Jan 14, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

10.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.5K

科学领域:

  • 神经免疫学 神经免疫学
  • 神经退行发生神经退行.
  • 中枢神经系统疾病 中枢神经系统疾病

背景情况:

  • 多发性硬化症 (MS) 是一种自身免疫性中枢神经系统疾病,具有遗传和环境风险因素.
  • 虽然已知复发和进展过程,但疾病进展现在被认为是MS患者神经障碍的主要驱动因素.
  • 了解MS进展的病理生理学对于开发向疗法至关重要.

研究的目的:

  • 突出疾病进展在多发性硬化症中累积神经障碍中的关键作用.
  • 强调需要定义驱动多发性硬化症进展的主导病理生理过程.
  • 讨论提升知识对开发向免疫调节疗法的影响.

主要方法:

  • 审查目前对MS病理生理学的理解,重点关注渐进的方面.
  • 分析病理特征,包括中枢神经系统炎症和神经退行.
  • 检查不断发展的临床试验设计和对MS进展的评估措施.

主要成果:

  • 渐进性因素是所有多发性硬化症临床课程中神经障碍累积的主要因素.
  • 病理学特征包括分隔的中枢神经系统炎症和神经退行性过程,导致神经轴和突触损失.
  • 对病理生理学的日益增长的理解支持针对渐进性MS的向免疫调节治疗的开发.

结论:

  • 定义驱动多发性硬化症进展的主导病理生理过程是必不可少的.
  • 新的临床试验设计和先进的评估措施为个性化治疗方案提供了机会.
  • 针对性免疫调节疗法正在出现,基于改善的病理生理学理解,治疗渐进性多发性硬化.